1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
------------------------
Date of Report (Date of earliest event reported): June 6, 1996
------------
IMMUNOGEN, INC.
---------------
(Exact name of registrant as specified in its charter)
Massachusetts 0-17999 04-2726691
- ------------- ------- ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
128 Sidney Street, Cambridge, Massachusetts 02139
-------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: (617) 661-9312
--------------
2
ITEM 5. OTHER EVENTS
- ------- ------------
On June 6, 1996, the Registrant amended its agreement with Capital Ventures
International dated March 15, 1996. This amendment is filed as Exhibit 10.29
hereto and incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
- ------- ---------------------------------
(c) Exhibits.
10.29 Letter Agreement dated as of June 6, 1996 by and among the
Registrant and Capital Ventures International regarding an
Amendment to their agreement dated March 15, 1996
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ImmunoGen, Inc.
---------------
(Registrant)
Date: June 10, 1996 /s/ Frank J. Pocher
------------- -------------------
Frank J. Pocher
Vice President and
principal financial officer
3
4
EXHIBIT INDEX
-------------
Exhibit Sequential
Number Description Page Number
- ------- ----------- -----------
10.29 Letter Agreement dated as of
June 6, 1996 by and among the
Registrant and Capital Ventures
International regarding an amendment
to their agreement dated March 15, 1996. 5
4